FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1157-1158 March 17, 2005 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Polyomavirus type BK nephropathy is an aggressively destructive disease occurring in up to 8 percent of patients with renal allografts,^1,2 with rates of graft loss within one year of 30 to 65 percent.^3,4 There is no therapy with proven efficacy. Leflunomide (Arava), approved for the treatment of rheumatoid arthritis, is an immunosuppressive drug, yet its active metabolite, A77 1726, has substantial antiviral activity in vitro and in animals.⁵

From July 2001 to April 2004, we used leflunomide as the initial antiviral therapy in 17 patients with biopsy-proven BK nephropathy. All but one of these patients was receiving . . . [Full Text of this Article]

This article has been cited by other articles:

• Singh, H. K., Andreoni, K. A., Madden, V., True, K., Detwiler, R., Weck, K., Nickeleit, V. (2009). Presence of Urinary Haufen Accurately Predicts Polyomavirus Nephropathy. J. Am. Soc. Nephrol. 20: 416-427 [Abstract] [Full Text]  
• Baumann, P., Mandl-Weber, S., Volkl, A., Adam, C., Bumeder, I., Oduncu, F., Schmidmaier, R. (2009). Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Molecular Cancer Therapeutics 8: 366-375 [Abstract] [Full Text]  
• Weiss, A. S., Gralla, J., Chan, L., Klem, P., Wiseman, A. C. (2008). Aggressive Immunosuppression Minimization Reduces Graft Loss Following Diagnosis of BK Virus-Associated Nephropathy: A Comparison of Two Reduction Strategies. CJASN 3: 1812-1819 [Abstract] [Full Text]  
• Wu, J. K, Harris, M. T (2008). Use of Leflunomide in the Treatment of Polyomavirus BK-Associated Nephropathy. The Annals of Pharmacotherapy 42: 1679-1685 [Abstract] [Full Text]  
• Leca, N., Muczynski, K. A., Jefferson, J. A., de Boer, I. H., Kowalewska, J., Kendrick, E. A., Pichler, R., Davis, C. L. (2008). Higher Levels of Leflunomide Are Associated with Hemolysis and Are not Superior to Lower Levels for BK Virus Clearance in Renal Transplant Patients. CJASN 3: 829-835 [Abstract] [Full Text]  
• Mannon, R. B. (2008). Leflunomide Therapy in Kidney Transplantation: Ready for Prime Time?. CJASN 3: 652-653 [Full Text]  
• Dall, A., Hariharan, S. (2008). BK Virus Nephritis after Renal Transplantation. CJASN 3: S68-S75 [Abstract] [Full Text]  
• Blanckaert, K., De Vriese, A. S. (2006). Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant 21: 3364-3367 [Full Text]  
• Teschner, S., Geyer, M., Wilpert, J., Schwertfeger, E., Schenk, T., Walz, G., Donauer, J. (2006). Remission of polyomavirus-induced graft nephropathy treated with low-dose leflunomide. Nephrol Dial Transplant 21: 2039-2040 [Full Text]  
• Djamali, A., Samaniego, M., Muth, B., Muehrer, R., Hofmann, R. M., Pirsch, J., Howard, A., Mourad, G., Becker, B. N. (2006). Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. CJASN 1: 623-640 [Abstract] [Full Text]  
• Wade, J. C. (2006). Viral Infections in Patients with Hematological Malignancies. ASH Education Book 2006: 368-374 [Abstract] [Full Text]  
• Chapman, J. R., O'Connell, P. J., Nankivell, B. J. (2005). Chronic Renal Allograft Dysfunction. J. Am. Soc. Nephrol. 16: 3015-3026 [Abstract] [Full Text]